Case ReviewsMolecular Testing of Lung CarcinomasDacic, Sanja MD, PhDAuthor Information From the Department of Pathology University of Pittsburgh, Pittsburgh, PA. Reprints: Sanja Dacic, MD, PhD, Department of Pathology, PUH C608, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, PA 15213. E-mail: [email protected]. The author confirms no funding or conflicts of interest to declare. Pathology Case Reviews: January/February 2014 - Volume 19 - Issue 1 - p 36-39 doi: 10.1097/PCR.0000000000000019 Buy Metrics Abstract Non–small cell lung carcinomas account for 80% to 85% of all lung cancers, with adenocarcinoma being the most common histologic type in the United States. Molecular testing for epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements are typically requested, with epidermal growth factor receptor mutations occurring in approximately 10% of adenocarcinomas from whites and approximately 50% in East Asians, usually in never-smoking patients and women. Anaplastic lymphoma kinase occurs in approximately 5% of lung adenocarcinoma patients. This review discusses the importance of molecular testing to help guide targeted therapy, which has become a standard practice. © 2014 by Lippincott Williams & Wilkins.